Profile
Chia-Feng Lu is a trusted advisor to investors, companies, and industry associations at the forefront of deep technology—where innovation intersects with complex regulatory regimes and national security considerations. He guides clients through the most challenging transactional and regulatory landscapes, helping them bring transformative technologies to market while safeguarding compliance and advancing strategic business goals.
Chia-Feng represents leading technology companies in high-stakes regulatory and legislative processes, working closely with policymakers to shape new laws, frameworks, and industry standards. His practice spans the development and commercialization of next-generation technologies, including advanced materials, artificial intelligence, biotechnology, quantum computing, robotics, semiconductors, and space. Over the past two decades, he has counseled on products grounded in Nobel Prize-winning science—one of which achieved blockbuster status in the pharmaceutical sector.
With a focus on cross-border corporate and regulatory law, Chia-Feng advises clients on mergers and acquisitions, strategic alliances, licensing, life-cycle management, and compliance strategies. His counsel is especially valued for addressing the rapidly evolving legal paradigms that govern deep technology across multiple jurisdictions.
Chia-Feng’s global perspective is central to his work. He regularly assists companies in navigating U.S. regulatory requirements while also providing insight into key markets across Europe, North Asia, and China. He counsels investment banks, private equity firms, and venture capital groups on regulatory developments, compliance challenges, and business risks in emerging technologies and sensitive supply chains.
Earlier in his career, Chia-Feng gained in-house experience with a U.S.-based global biotechnology company and a Japan-based global pharmaceutical leader, giving him a first-hand understanding of organizational priorities and the business realities facing technology-driven enterprises. Beyond his client work, he serves as an adjunct faculty member at leading academic institutions and holds advisory positions with several governments on policy development related to artificial intelligence, cell and gene therapy, robotics, semiconductors, shipbuilding, and the defense industry.
Through this combination of legal acumen, policy influence, and industry insight, Chia-Feng is widely recognized as a global strategic advisor for clients operating at the cutting edge of science, technology, and national security.
Concentrations
- Innovation and commercialization of life sciences and emerging technology
- Overseas market entry
- Strategic transactions in life sciences and emerging technology
- Regulatory laws
- Corporate compliance and governance
- Export control and international trade
- Intellectual property and privacy
Capabilities
Experience
- Represented a leading pharma’s acquisition of a NASDAQ-listed biotech company focusing on cancer therapies and treatments in a cash tender offer followed by a merger for a total equity value of $2.4 billion, as well as relevant post-merger work.
- Advised a leading Boston-based biotechnology company on the regulatory strategy of its leading neurodegenerative medicine.
- Advised a leading semiconductor company on its joint-venture and collaboration project and resulting possible export control and trade issues.
- Advised a leading bioventure in anti-infectious diseases area on its dispute with global contract research organization.
- Advised a leading IoT company on development of its compliance program across multiple jurisdictions in the U.S. and in Europe from regulatory, antitrust, and data privacy perspectives.
- Advised a bioventure on its license of its early-stage asset in Kennedy's disease to a NASDAQ-listed biotech company.
- Advised a leading pharmaceutical company on the co-development strategy for a drug-biologic combination regime from the regulatory and market access perspectives in the U.S. and in Europe.
- Advised a leading pharmaceutical company on its introduction of AI tool in empowerment of its drug discovery activity and on its partnership with such AI company for the license.
- Advised on a leading technology conglomerate on its acquisition of a laboratory-developed testing company in the United States.
- Advised a leading biotech company on its risk-sharing clinical trial collaboration with a contract research organization on its lead ophthalmology product, including the investment from such contract research organization.
- Advised a leading pharmaceutical company on its novel cell therapy portfolio’s regulatory strategy, policy advocacies, life cycle management approach, and strategic partnership transactions in multiple jurisdictions.
- Represented a U.S. and a Japanese pharmaceutical company in their co-developed cancer immunotherapy regarding legal matters related to the product launch in multiple jurisdictions.
- Advised on various legal and regulatory issues underlying the product development of a digital health product, including its AI component, developed by a U.S. technology conglomerate in more than thirty jurisdictions.°
- Represented a U.S. global biotechnology company in its contract manufacturing partnership negotiation with several contract development and manufacturing organizations for its CAR-T therapy in multiple jurisdictions.°
- Led the regulatory, policy, and legal advisory to a leading U.S. biotechnology company's launch of SiRNA therapy in several jurisdictions.°
- Led a strategic investment in a microbio company together with leading venture capitals and the Bill & Melinda Gates Foundation.°
- Advised a Japanese conglomerate on its acquisition of a U.S. diagnostic company to increase its precision medicine capacity in the US, the following post-merger integration, as well as the relevant FDA regulatory issues of the development of the novel diagnostics.°
- Represented a global biotech company to resolve its dispute with its regional partner on a co-promotion partnership of its blockbuster.
- Led the initiative to prepare and implement global policies and procedures, such as anti-bribery, sponsorship, donation, fair market value, transparency, interactions with the stakeholders, cross-border data transfer, hotline/helpline, on behalf of multiple top global pharmaceutical companies.°
- Defended a lead biotechnology company against a government's investigation concerning its unfair competition practices, which was raised from its competitor.°
- Advised a U.S. health care conglomerate on numerous legal issues surrounding its establishment of an innovation incubation center affiliated with a health care institution in Gulf area.°
- Advised on a leading biotechnology company's authorized generic strategy of its blockbuster cancer product.°
- Served as the external general counsel to numerous biotech or emerging technology companies in the U.S. and in Europe.°
°The above representations were handled by Mr. Lu prior to his joining Greenberg Traurig, LLP.
- Takeda Pharmaceutical Company
- Celgene
Recognition & Leadership
- Listed, Chambers USA Guide, "Up and Coming," Healthcare: Pharmaceutical/Medical Products Regulatory, 2024-2025
- Shortlisted, LMG Life Sciences, 2023-2024
- "US Rising Star – Regulatory," 2023
- "US Rising Star – Financial & Corporate," 2024
- Listed, The Best Lawyers in America, "Ones to Watch," Health Care Law, 2021-2025
- Listed, The Legal 500 United States,
- Healthcare: Life Sciences, 2024-2025
- Healthcare: Service Providers, 2022 and 2023
- NOME Mentor, Nordic Mentor Network for Entrepreneurship (NOME)
Credentials
- J.D., University of Houston Law Center
- B.S., Pharmacy (Major) and Economics (Minor), National Taiwan University
- District of Columbia
- New York
- English, Fluent
- Japanese, Conversational
- Chinese (Mandarin), Native
- Chinese (Cantonese), Basic
- Taiwanese, Native